Receptor News and Research

RSS

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Social scientists say compassion is humans' strongest trait

Researchers at UC Berkeley are challenging long-held beliefs that human beings are wired to be selfish. In a wide range of studies, social scientists are amassing a growing body of evidence to show we are evolving to become more compassionate and collaborative in our quest to survive and thrive.

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Smell and sexual reproduction

Humans have the same receptors for detecting odors related to sex as do other apes and primates. But each species uses them in different ways, stemming from the way the genes for these receptors have evolved over time, according to Duke University researchers.

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

Statewide blood screening program identifies infants with T-cell lymphopenia

The testing of DNA from a statewide blood screening program for newborns in Wisconsin was able to identify infants with T-cell lymphopenia, a blood disorder that affects the child's immune system, a disease in which early identification is important, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Soy food beneficial for women with breast cancer

Although there is a concern regarding the safety of soy food consumption among breast cancer survivors, researchers have found that women in China who had breast cancer and a higher intake of soy food had an associated lower risk of death and breast cancer recurrence, according to a study in the December 9 issue of JAMA.

9 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx, Incorporated today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

8 Dec 2009

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

Scientists identify aggression-promoting pheromone in flies’ antenna

Have you ever found yourself struggling to get your order taken at a crowded bar or lunch counter, only to walk away in disgust as more aggressive customers elbow their way to the front? It turns out that flies do much the same thing, according to biologists from the California Institute of Technology (Caltech).

7 Dec 2009

Receptor News and Research

YM BioSciences announces results of collaborative antibody development program

Social scientists say compassion is humans' strongest trait

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Smell and sexual reproduction

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Statewide blood screening program identifies infants with T-cell lymphopenia

Soy food beneficial for women with breast cancer

New guidelines on the management of antithrombotic agents for endoscopic procedures published

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Xanthohumol compound may aid in preventing prostate cancer

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Ambit Biosciences presents study results of its AC220 FLT3 inhibitor for AML

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Social isolation and stress can raise breast cancer risk

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Scientists identify aggression-promoting pheromone in flies’ antenna

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News